Amedisys (AMED) Competitors

Chemed (NYSE:CHE) and Amedisys (NASDAQ:AMED) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, community ranking, media sentiment, profitability, risk, dividends, earnings and institutional ownership.

Which has more risk and volatility, CHE or AMED?

Chemed has a beta of 0.42, suggesting that its stock price is 58% less volatile than the S&P 500. Comparatively, Amedisys has a beta of 0.86, suggesting that its stock price is 14% less volatile than the S&P 500.

Does the MarketBeat Community favor CHE or AMED?

Amedisys received 166 more outperform votes than Chemed when rated by MarketBeat users. However, 63.44% of users gave Chemed an outperform vote while only 59.02% of users gave Amedisys an outperform vote.

Company	Underperform	Outperform
Chemed	Outperform Votes 328 63.44%	Underperform Votes 189 36.56%
Amedisys	Outperform Votes 494 59.02%	Underperform Votes 343 40.98%

Does the media favor CHE or AMED?

In the previous week, Chemed had 3 more articles in the media than Amedisys. MarketBeat recorded 7 mentions for Chemed and 4 mentions for Amedisys. Amedisys' average media sentiment score of 0.76 beat Chemed's score of 0.71 indicating that Chemed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Chemed	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Amedisys	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is CHE or AMED more profitable?

Chemed has a net margin of 12.03% compared to Chemed's net margin of -0.44%. Amedisys' return on equity of 32.29% beat Chemed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Chemed	12.03%	32.29%	20.74%
Amedisys	-0.44%	12.76%	7.02%

Do institutionals & insiders hold more shares of CHE or AMED?

95.9% of Chemed shares are held by institutional investors. Comparatively, 94.4% of Amedisys shares are held by institutional investors. 3.3% of Chemed shares are held by company insiders. Comparatively, 1.8% of Amedisys shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Do analysts prefer CHE or AMED?

Chemed currently has a consensus price target of $681.00, suggesting a potential upside of 10.81%. Amedisys has a consensus price target of $97.50, suggesting a potential upside of 6.62%. Given Amedisys' stronger consensus rating and higher probable upside, analysts plainly believe Chemed is more favorable than Amedisys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chemed	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Amedisys	0 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.13

Which has preferable earnings & valuation, CHE or AMED?

Chemed has higher revenue and earnings than Amedisys. Amedisys is trading at a lower price-to-earnings ratio than Chemed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Chemed	$2.26B	4.13	$272.51M	$17.92	34.49
Amedisys	$2.24B	1.34	-$9.75M	-$0.31	-295.31

Summary

Chemed beats Amedisys on 16 of the 18 factors compared between the two stocks.